New Zealand markets closed
  • NZX 50

    11,103.79
    -21.41 (-0.19%)
     
  • NZD/USD

    0.5632
    -0.0032 (-0.56%)
     
  • NZD/EUR

    0.5757
    -0.0022 (-0.39%)
     
  • ALL ORDS

    6,976.10
    -57.40 (-0.82%)
     
  • ASX 200

    6,762.80
    -54.70 (-0.80%)
     
  • OIL

    88.41
    -0.04 (-0.05%)
     
  • GOLD

    1,720.20
    -0.60 (-0.03%)
     
  • NASDAQ

    11,485.50
    -87.70 (-0.76%)
     
  • FTSE

    6,997.27
    -55.35 (-0.78%)
     
  • Dow Jones

    29,926.94
    -346.96 (-1.15%)
     
  • DAX

    12,470.78
    -46.42 (-0.37%)
     
  • Hang Seng

    17,793.22
    -218.93 (-1.22%)
     
  • NIKKEI 225

    27,116.11
    -195.19 (-0.71%)
     
  • NZD/JPY

    81.6230
    -0.5060 (-0.62%)
     

Is Apexigen (NASDAQ:APGN) In A Good Position To Deliver On Growth Plans?

·4-min read

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

So, the natural question for Apexigen (NASDAQ:APGN) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.

Check out our latest analysis for Apexigen

Does Apexigen Have A Long Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at March 2022, Apexigen had cash of US$28m and no debt. Looking at the last year, the company burnt through US$25m. That means it had a cash runway of around 13 months as of March 2022. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Apexigen's Cash Burn Changing Over Time?

Because Apexigen isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 21%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. Apexigen makes us a little nervous due to its lack of substantial operating revenue. So we'd generally prefer stocks from this list of stocks that have analysts forecasting growth.

How Easily Can Apexigen Raise Cash?

Given its cash burn trajectory, Apexigen shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Apexigen's cash burn of US$25m is about 12% of its US$215m market capitalisation. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted.

Is Apexigen's Cash Burn A Worry?

On this analysis of Apexigen's cash burn, we think its cash burn relative to its market cap was reassuring, while its increasing cash burn has us a bit worried. We don't think its cash burn is particularly problematic, but after considering the range of factors in this article, we do think shareholders should be monitoring how it changes over time. On another note, we conducted an in-depth investigation of the company, and identified 4 warning signs for Apexigen (3 are a bit unpleasant!) that you should be aware of before investing here.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here